- Home
- FOUR vs VERA Comparison
FOUR vs VERA Comparison
Compare FOUR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOUR | VERA |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FOUR | VERA |
|---|---|---|
| Price | $44.38 | $46.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 10 |
| Target Price | ★ $85.04 | $81.30 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,180,000,000.00 | N/A |
| Revenue This Year | $23.83 | N/A |
| Revenue Next Year | $14.30 | $472.48 |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $39.91 | $18.76 |
| 52 Week High | $107.16 | $56.05 |
Technical Indicators
Market Signals| Indicator | FOUR | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 68.75 |
| Support Level | $41.96 | $44.56 |
| Resistance Level | $76.31 | $56.05 |
| Average True Range (ATR) | 3.56 | 2.29 |
| MACD | 0.27 | 0.57 |
| Stochastic Oscillator | 28.48 | 90.66 |
Price Performance
Historical ComparisonAbout FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.